MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that management will present an overview of the company's business at Cantor Fitzgerald’s Healthcare Conference.
The presentation is scheduled for 9:30 a.m. ET on Wednesday, July 8, 2015, at the Le Parker Meridien Hotel in New York City.
A replay of the presentation will be available via the investors section of the company's website at www.intersectENT.com. The webcast replay will be available approximately 24 hours after the live presentation and will be archived for approximately one month.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.